IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PUOTI, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.357
AS - Asia 2.956
EU - Europa 2.214
SA - Sud America 462
AF - Africa 49
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 13
Totale 12.069
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.288
CN - Cina 1.128
SG - Singapore 967
UA - Ucraina 746
DE - Germania 414
BR - Brasile 403
HK - Hong Kong 354
FI - Finlandia 208
IT - Italia 177
GB - Regno Unito 152
TR - Turchia 126
IN - India 119
RU - Federazione Russa 117
IE - Irlanda 114
PL - Polonia 112
VN - Vietnam 112
FR - Francia 51
CA - Canada 41
SE - Svezia 38
BD - Bangladesh 34
ZA - Sudafrica 23
AR - Argentina 20
IQ - Iraq 19
MX - Messico 19
JP - Giappone 17
BE - Belgio 16
AU - Australia 14
EU - Europa 13
NL - Olanda 12
VE - Venezuela 12
EC - Ecuador 11
LT - Lituania 11
SA - Arabia Saudita 10
AT - Austria 9
ES - Italia 9
IR - Iran 9
PK - Pakistan 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 6
CO - Colombia 6
IL - Israele 6
MA - Marocco 5
AZ - Azerbaigian 4
ID - Indonesia 4
KE - Kenya 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
BG - Bulgaria 3
CL - Cile 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BY - Bielorussia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
RS - Serbia 2
AL - Albania 1
AO - Angola 1
BF - Burkina Faso 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GY - Guiana 1
HN - Honduras 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LR - Liberia 1
LV - Lettonia 1
LY - Libia 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
TM - Turkmenistan 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 12.069
Salva come PNG Salva come JPEG
Città #
Woodbridge 766
Fairfield 665
Ashburn 590
Jacksonville 553
Houston 485
Singapore 460
Hong Kong 354
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 304
Nanjing 228
Princeton 193
Chandler 177
Beijing 169
Los Angeles 114
Dublin 113
Warsaw 111
Istanbul 102
New York 101
Helsinki 92
Nanchang 90
Dearborn 80
The Dalles 76
Moscow 70
Shenyang 59
Des Moines 53
Changsha 48
Munich 47
Buffalo 46
San Diego 46
Shanghai 46
Ho Chi Minh City 43
Jinan 43
Tianjin 43
Hebei 41
São Paulo 40
Jiaxing 36
Lancaster 33
Milan 33
San Francisco 33
Redondo Beach 32
Brescia 30
London 29
Washington 28
Verona 21
Kunming 20
Toronto 18
Brooklyn 17
Chicago 17
Hangzhou 17
Hanoi 17
Tokyo 17
Brussels 16
Charlotte 16
Dallas 16
Lanzhou 16
Taizhou 16
Kocaeli 15
Rio de Janeiro 15
Santa Clara 15
Zhengzhou 15
Guangzhou 14
Leawood 13
San Mateo 13
Brasília 12
Chennai 12
Johannesburg 12
Denver 11
Haikou 11
Monmouth Junction 11
Norwalk 11
Atlanta 10
Stockholm 10
Augusta 9
Belo Horizonte 9
Boston 9
Campinas 9
Delhi 9
Ningbo 9
Orem 9
Porto Alegre 9
Ardabil 8
Melbourne 8
Nuremberg 8
Turku 8
Curitiba 7
Hefei 7
Manchester 7
Mexico City 7
Tashkent 7
Erbil 6
Mumbai 6
Orange 6
Poplar 6
Taiyuan 6
Caruaru 5
Caxias do Sul 5
Dhaka 5
Fuzhou 5
Totale 8.296
Salva come PNG Salva come JPEG
Nome #
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 181
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 180
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 177
Use of brain MRI in manganese exposure 176
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 167
Antiretroviral drugs and liver injury. 163
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 157
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 156
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 154
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 153
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 151
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 145
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 143
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 143
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 142
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 140
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 139
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 139
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 137
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 137
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 136
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 131
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 131
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 128
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 126
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 125
Polymorphic immune restoration syndrome after effective HAART 125
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 122
Care of patients with hepatitis C and HIV co-infection. 122
Mortality for liver disease in patients with HIV infection: a cohort study 122
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 121
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 120
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 118
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 116
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 114
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 114
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 114
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 113
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 113
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 113
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 113
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 113
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 112
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 110
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 110
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 109
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 108
HIV/HCV co-infection: natural history. 108
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 107
Natural history of chronic hepatitis B in co-infected patients. 107
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 107
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 107
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 106
The burden of HIV and hepatitis C virus coinfection. 106
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 106
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 105
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 105
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 105
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 105
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 104
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 104
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 104
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 104
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 104
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 104
Impact of hepatitis C virus infection on lifestyle. 103
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 103
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 103
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 103
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 102
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 102
HCV chronic hepatitis in patients with HIV: clinical management issues 102
The use of molecular assays in the management of viral hepatitis. 102
Management of hepatitis C in human immunodeficiency virus-infected patients. 102
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 102
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 101
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 101
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 100
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 99
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 99
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 99
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 98
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 97
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 95
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 95
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 94
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 89
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 88
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 87
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 86
HCV infection: pathogenesis, clinical manifestations and therapy. 85
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 84
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome 84
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 81
Risk of developing specific AIDS-defining illnesses in patients coinfected withHIV and hepatitis C virus with or without liver cirrhosis 80
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 77
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 77
Pathogenesis of liver damage in HCV-HIV patients. 75
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 73
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. 72
Totale 11.417
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021974 0 0 0 0 0 149 82 155 244 110 196 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/20251.702 8 4 7 237 213 158 156 39 150 148 372 210
2025/20261.900 352 484 166 395 382 121 0 0 0 0 0 0
Totale 12.174